8-K: Ainos Inc. Reports Full Year 2024 Financial Results, Pivoting Towards AI Nose and VELDONA Technologies

Ainos, Inc. announces its financial results for fiscal year 2024, highlighting a strategic shift from COVID-19 testing to AI Nose and VELDONA technologies.

Summary

• Ainos, Inc. reported its financial results for the fiscal year ended December 31, 2024.
• The company is transitioning from its COVID-19 antigen rapid test business to focus on VELDONA and AI Nose programs.
• Revenues for 2024 were US$20,729, compared to US$122,112 in 2023, reflecting lower sales of COVID-19 tests.
• The company experienced a negative gross profit of US$31,866 in 2024, narrowing from negative US$253,733 in 2023.
• Total operating expenses were US$13,809,338 in 2024, compared to US$12,952,663 in 2023, primarily due to increased co-research and staffing expenditures.
• R&D expenses increased to US$8,413,923 in 2024 from US$7,317,388 in 2023.
• SG&A expenses decreased to US$5,395,415 in 2024 from US$5,635,275 in 2023.
• Net loss attributable to common stock shareholders was US$14,863,161 in 2024, compared to US$13,770,549 in 2023.
• As of December 31, 2024, the company had cash and cash equivalents of US$3,892,919, compared to US$1,885,628 as of December 31, 2023.
• Ainos is partnering with Taiwan Tanabe Seiyaku to advance VELDONA for Sjgrens syndrome in Taiwan.
• The company received IRB approval for a clinical trial of VELDONA in treating Sjgrens syndrome.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is making progress in new technology areas like AI Nose and VELDONA, the financial results show a significant decline in revenue and a net loss. The shift in focus could be promising, but the current financial situation raises concerns.

Positives

• Ainos is making progress in AI Nose technology with high accuracy rates in clinical trials.
• The company is expanding AI Nose applications into industrial and robotics sectors.
• VELDONA drug development is advancing with clinical studies planned for HIV oral warts and Sjgrens syndrome.
• Ainos has secured a partnership with Taiwan Tanabe Seiyaku.
• The company obtained a pivotal invention patent in Japan.
• Cash and cash equivalents increased year over year.

Negatives

• Revenues decreased significantly due to lower sales of COVID-19 antigen rapid test kits.
• The company reported a negative gross profit for the fiscal year 2024.
• The company experienced a net loss attributable to common stock shareholders of US$14,863,161 in 2024.

Risks

• The company's ability to raise additional capital to continue product development is a risk.
• Delays in completing the development and commercialization of product candidates could impact future results.
• Competition in the marketplace poses a risk to the company's success.
• Compliance with applicable laws, regulations, and tariffs could impact the company's operations.

Future Outlook

Ainos remains committed to accelerating innovation, strengthening strategic partnerships, and expanding its IP portfolio to reinforce its leadership in AI Nose development and immunotherapy, while prioritizing investments in core technology platforms and pursuing strategic partnerships to accelerate commercialization.

Management Comments

• Chun-Hsien (Eddy) Tsai stated that 2024 marked a pivotal year as the company transitioned from COVID-19 antigen rapid test business to advancing the VELDONA and pioneering AI Nose programs.
• Christopher Lee commented that Ainos remains capital-efficient and prudent in strategically allocating resources to advance key programs while maintaining financial flexibility.

Industry Context

Ainos' shift towards AI Nose technology aligns with the growing trend of AI-driven diagnostics and telehealth solutions. The company's focus on VOC detection in industrial settings also taps into the increasing demand for enhanced safety and efficiency in sectors like semiconductor manufacturing. The partnership with Taiwan Tanabe Seiyaku reflects a broader industry trend of collaboration to accelerate drug development and commercialization.

Comparison to Industry Standards

• Ainos' AI Nose technology, with up to 94% accuracy in clinical trials for Ainos Flora, positions it competitively against other point-of-care diagnostic companies like Cue Health and Visby Medical, which are also developing rapid diagnostic tests.
• The company's VOC detection platform, with nearly 80% accuracy in identifying 22 different VOCs in semiconductor factories, is comparable to solutions offered by companies like Sensirion and AMS, which specialize in environmental sensing and gas detection.
• Ainos' partnership with Taiwan Tanabe Seiyaku for VELDONA development mirrors similar collaborations in the pharmaceutical industry, such as the partnership between Novartis and Molecular Partners for the development of antiviral therapies.

Stakeholder Impact

• Shareholders may be concerned about the decline in revenue and net loss, but encouraged by the company's focus on new technologies.
• Employees may experience changes as the company shifts its focus and resources.
• Customers may benefit from the development of new AI Nose and VELDONA technologies.
• Suppliers may see changes in demand as the company's product focus shifts.
• Creditors will be monitoring the company's financial performance and ability to repay debts.

Next Steps

• Commence clinical studies for the second-generation Ainos Flora in H1 2025.
• Pursue mass production of the AI-powered VOC detection platform in H1 2025.
• Begin clinical studies for HIV oral warts and Sjgrens syndrome in Taiwan this year.
• Submit Investigational New Drug (IND) applications to the U.S. Food and Drug Administration by H2 2025.

Key Dates